Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)

Kronos Bio, Inc. announced the US FDA has cleared its Investigational New Drug Application for LANRA, allowing the company to proceed with a Phase I/II clinical trial of LANRA in patients with relapsed or refractory FLT3-mutated AML in combination with gilteritinib.